The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as, for example, ricin, and of viruses that use the internalization pathway for infecting cells.

RhlR modulators including agonist and antagonists which are useful for modulating QS phenotypes in Gram-negative bacteria. Certain compounds of general formula A-W-HG having various carbocyclic ad heterocyclic head groups (HG) and various tail groups (A), where —W— is —CO—NH—, —SO.sub.2—NH—, —CO—NH—CH.sub.2—, or —SO.sub.2—NH—CH.sub.2— are RhlR agonists or antagonists. The compounds are useful in methods of modulating quorum sensing in Gram-negative bacteria, particularly in Pseudomonas. Compositions including certain RhlR modulators are useful for decreasing the virulence of Gram-negative bacteria. Pharmaceutical compositions comprising certain RhlR modulators are useful for treatment of infections of Gram-negative bacteria.

RhlR modulators including agonist and antagonists which are useful for modulating QS phenotypes in Gram-negative bacteria. Certain compounds of general formula A-W-HG having various carbocyclic ad heterocyclic head groups (HG) and various tail groups (A), where —W— is —CO—NH—, —SO.sub.2—NH—, —CO—NH—CH.sub.2—, or —SO.sub.2—NH—CH.sub.2— are RhlR agonists or antagonists. The compounds are useful in methods of modulating quorum sensing in Gram-negative bacteria, particularly in Pseudomonas. Compositions including certain RhlR modulators are useful for decreasing the virulence of Gram-negative bacteria. Pharmaceutical compositions comprising certain RhlR modulators are useful for treatment of infections of Gram-negative bacteria.

The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease, Alzheimer's disease and/or Gaucher's disease.

The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease, Alzheimer's disease and/or Gaucher's disease.

Compounds are provided having the following structure:

##STR00001##

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.3, L.sup.1, L.sup.2, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

Described herein is a polymeric stabilizing agent selected from poly-lysine derivatives obtained by process including heating an aqueous lysine solution to boiling, increasing a temperature of the aqueous lysine solution to a reaction temperature in the range of about 105° C. to about 180° C., and keeping the reaction temperature in the range of about 105° C. to about 180° C. until a melt viscosity of the reaction mixture is in the range of about 350 mPa*s to about 6,500 mPa*s, and (ii) an amine number in the range of about 100 mg KOH/g to about 500 mg KOH/g is achieved. The process also includes adding alkyl-carboxylic acid or alkenyl-carboxylic acid in amounts of 2.5 mol % to 10 mol %, and increasing or keeping the reaction temperature in the range of about 105° C. to about 180° C. until number of free alkyl-carboxylic acid or alkenyl-carboxylic acid is ≤9% by weight.

Described herein is a polymeric stabilizing agent selected from poly-lysine derivatives obtained by process including heating an aqueous lysine solution to boiling, increasing a temperature of the aqueous lysine solution to a reaction temperature in the range of about 105° C. to about 180° C., and keeping the reaction temperature in the range of about 105° C. to about 180° C. until a melt viscosity of the reaction mixture is in the range of about 350 mPa*s to about 6,500 mPa*s, and (ii) an amine number in the range of about 100 mg KOH/g to about 500 mg KOH/g is achieved. The process also includes adding alkyl-carboxylic acid or alkenyl-carboxylic acid in amounts of 2.5 mol % to 10 mol %, and increasing or keeping the reaction temperature in the range of about 105° C. to about 180° C. until number of free alkyl-carboxylic acid or alkenyl-carboxylic acid is ≤9% by weight.

Described herein is a poly-lysine derivative obtained by a process including heating an aqueous lysine solution to boiling, increasing a temperature of the aqueous lysine solution to a reaction temperature in the range of about 105° C. to about 180° C., and keeping the reaction temperature in the range of about 105° C. to about 180° C. until (i) a melt viscosity of the reaction mixture is in the range of about 350 mPa*s to about 6,500 mPa*s, and (ii) an amine number in the range of about 100 mg KOH/g to about 500 mg KOH/g is achieved. The process also includes adding alkyl-carboxylic acid or alkenyl-carboxylic acid in amounts of 2.5 mol % to 10 mol %, and increasing or keeping the reaction temperature in the range of about 105° C. to about 180° C. until number of free alkyl-carboxylic acid or alkenyl-carboxylic acid is ≤9% by weight.